Josh Arnold Investment Consultant’s Adaptimmune Therapeutics ADAP Stock Holding History

Josh Arnold Investment Consultant’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$37.8K	–	14
2025 Q4	$37.8K	Buy	+20,000	New	+$2.72K	0.03%	15

Other funds holding ADAP

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Josh Arnold Investment Consultant's ADAP Position: Q1 2026 in Review

Josh Arnold Investment Consultant sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 20,000 shares — an estimated $37.8K sold.

Josh Arnold Investment Consultant first reported a position in ADAP in Q4 2025 and held it in 1 quarter. The position peaked at $37.8K in Q4 2025. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.

Josh Arnold Investment Consultant reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
Josh Arnold Investment Consultant sold 20,000 Adaptimmune Therapeutics shares in Q1 2026, an estimated $37.8K.
Josh Arnold Investment Consultant first reported a position in Adaptimmune Therapeutics in Q4 2025 and held it in 1 quarter.
Josh Arnold Investment Consultant's Adaptimmune Therapeutics position peaked at $37.8K in Q4 2025.
1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.

Based on Josh Arnold Investment Consultant's 13F filing for Q1 2026, filed 15 May 2026.